Gantenerumab is a monoclonal antibody for the treatment of Alzheimer's disease being developed by Hoffmann-La Roche pharmaceuticals.
Gantenerumab binds to and clears aggregated beta amyloid fibers.
A phase III clinical trial of gantenerumab was stopped early because of a lack of efficacy. From Wikipedia
